¡Ø Ãß¼® ¿¬ÈÞ ÈÞ¹«¾È³» : 2024³â 9¿ù 16ÀÏ(¿ù) ~ 2024³â 9¿ù 18ÀÏ(¼ö)

½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1500319

¼¼°èÀÇ ºê·¹ÀÎ ¸ÅÇÎ ±â±â ½ÃÀå(2024-2031³â)

Global Brain Mapping Instruments Market 2024-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Orion Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 135 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ºê·¹ÀÎ ¸ÅÇÎ ±â±â ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2031³â) µ¿¾È ¿¬Æò±Õ 6.1%ÀÇ ³ôÀº ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼°è ºê·¹ÀÎ ¸ÅÇÎ ±â±â ½ÃÀåÀº ½Å°æ °úÇÐ ¿¬±¸ÀÇ ¹ßÀü, ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡, ±â¼ú Çõ½Å, Á¤ºÎ ¹× ¹Î°£ ÀÚ±Ý Áö¿ø, ÀÓ»ó Àû¿ë, ÀÎ½Ä °³¼± ¹× ±³À°, ¼¼°èÈ­, ÆÄÆ®³Ê½Ê, ±ÔÁ¦ »óȲ µî¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ½Å°æ°úÇÐ ¿¬±¸ÀÇ ¹ßÀü, »ó¼¼ÇÑ µ¥ÀÌÅ͸¦ ¾ò±â À§ÇÑ Á¤±³ÇÑ µµ±¸ÀÇ Çʿ伺, ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, °£Áú, ³úÁ¹Áß°ú °°Àº ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ³ú ¸ÅÇÎ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù. Á¤ºÎ ¹× ¹Î°£ ÀÚ±Ý Áö¿ø À̴ϼÅƼºê¿Í ³ú °Ç°­ ¹× Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¾÷°è, Çаè, ¿¬±¸±â°ü °£ÀÇ Çù·ÂÀº ºê·¹ÀÎ ¸ÅÇÎ ±â±âÀÇ ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

Áø´Ü ¹× ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ´ÏÁî Áõ°¡

¼¼°èÀÎÀÇ °Ç°­Àº ½Å°æÁúȯÀÇ À§Çè¿¡ ³ëÃâµÇ¾î ÀÖÀ¸¸ç, Á¤È®ÇÑ Áø´Ü°ú Áö¼ÓÀûÀÎ °üÂûÀÌ ÇÊ¿äÇÕ´Ï´Ù. ³ú ¸ÅÇÎÀ» À§ÇÑ µµ±¸´Â Áúº´ÀÇ ÁøÇà°ú Ä¡·á È¿°ú¿¡ ÇʼöÀûÀÔ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, 2024³â 3¿ù ±âÁØ Àü ¼¼°è ½Å°æÁúȯ À¯º´·üÀº 30¾ï ¸í ÀÌ»óÀÌ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ½Å°æÁúȯÀº Àü ¼¼°èÀûÀ¸·Î Áúº´°ú Àå¾ÖÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. À̵é ÁúȯÀ¸·Î ÀÎÇÑ Àå¾Ö, Áúº´ ¹× Á¶±â »ç¸ÁÀÇ Àüü ºÎ´ãÀº 18.0% Áõ°¡Çß½À´Ï´Ù. ÁÖ¸ñÇÒ ¸¸ÇÑ Á¡Àº ½Å°æÁúȯ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼º Â÷ÀÌ·Î, °í¼Òµæ ±¹°¡´Â ½Å°æÁúȯÀ¸·Î ÀÎÇÑ »ç¸Á ¹× °Ç°­ ¼Õ½ÇÀÇ 80.0% ÀÌ»óÀÌ ¹ß»ýÇÏ´Â ÁßÀú¼Òµæ ±¹°¡¿¡ ºñÇØ Àα¸ 10¸¸ ¸í´ç ½Å°æÁúȯ Àü¹®ÀÇ ¼ö°¡ ÈξÀ ´õ ¸¹´Ù´Â Á¡ÀÔ´Ï´Ù.

ºê·¹ÀÎ ¸ÅÇÎ ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø Áõ°¡

Brain Connects´Â ³ú ¸ÅÇÎ ¿¬±¸¿¡ ¸·´ëÇÑ ÀÚ±ÝÀ» Áö¿øÇÏ¿© »õ·Î¿î ±â¼ú °³¹ßÀ» ÃËÁøÇÏ°í, ÆÄÆ®³Ê½Ê, ±â¼úÀÌÀü, ¿¬±¸ Á¦Ç°ÀÇ »ó¿ëÈ­¸¦ ÅëÇØ ½ÃÀå °³Ã´À» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ±¹¸³½Å°æÁúȯ ¹× ³úÁ¹Áß ¿¬±¸¼Ò(NIH BRAIN Initiative)´Â 2023³â 9¿ù NIH BRAIN Initiative¸¦ ÅëÇØ ³ú¸¦ »ó¼¼ÇÏ°Ô ¸ÅÇÎÇÏ´Â Çõ½ÅÀûÀÎ ±â¼úÀ» °³¹ßÇÏ´Â ÇÁ·ÎÁ§Æ®¸¦ ½ÃÀÛÇß½À´Ï´Ù. ÀÌ À̴ϼÅƼºê´Â ³úÀÇ ½Å°æ ÄÚµåÀÇ ³í¸®¸¦ ¹àÈ÷´Â °ÍÀ» ¸ñÇ¥·Î Çϸç, ³úÀÇ ½Å°æ Äڵ尡 ¾î¶»°Ô ¿ì¸® ÀÚ½ÅÀ» ¸¸µå´ÂÁö, ±×¸®°í ³ú ÁúȯÀ» Ä¡·áÇϱâ À§ÇØ ³úÀÇ ½Å°æ Äڵ带 ¾î¶»°Ô Àç¹è¼±ÇÒ ¼ö ÀÖ´ÂÁö¸¦ ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù. ºê·¹ÀÎ Ä¿³ØÃ÷(BRAIN CONNECTS)ÀÇ Ã¹ ¹ø° Áö¿ø±ÝÀº ÃÑ 11°ÇÀ̸ç, 5³â°£ ÃÑ 1¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÕ´Ï´Ù. ÀÌ ÇÁ·ÎÁ§Æ®µéÀº ÃÖ÷´Ü ±â¼úÀ» »ç¿ëÇÏ¿© ³úÀÇ °áÇÕÀ» À̹ÌÁöÈ­ ¹× ºÐ¼®ÇÏ°í, µ¥ÀÌÅÍ ¼öÁý ¹× ºÐ¼®À» À§ÇÑ ÆÄÀÌÇÁ¶óÀÎÀ» °³¹ßÇÏ°í, º¸¿ÏÀûÀÎ ³ú ¸ÅÇÎ ±â¼úÀ» °³¹ßÇÒ ¿¹Á¤ÀÔ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¼¼°è ºê·¹ÀÎ ¸ÅÇÎ ±â±â ½ÃÀåÀ» ¼¼ºÎÀûÀ¸·Î ºÐ¼®ÇÑ °á°ú, Á¦Ç°º° ¹× ÃÖÁ¾»ç¿ëÀÚº°·Î ´ÙÀ½°ú °°ÀÌ ±¸ºÐÇÏ¿´½À´Ï´Ù.

  • Á¦Ç°º°·Î´Â ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(CAT), ¾çÀüÀÚ¹æ»ç´ÜÃþÃÔ¿µ(PET), ³úÆÄ(EEG), ±â´ÉÀû ±ÙÀû¿Ü¼± ºÐ±¤¹ý(fNIRS), ±â´ÉÀû ÀÚ±â°ø¸í¿µ»ó¹ý(fMRI), ±âŸ(³úÀÚ±â°ø¸í¿µ»ó(MEG) ½Ã½ºÅÛ, °æµÎ°³ ÀÚ±âÀÚ±Ø(TMS) ±â±â)·Î ¼¼ºÐÈ­µË´Ï´Ù.
  • ÃÖÁ¾»ç¿ëÀÚº°·Î º¸¸é ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, Áø´Ü¼¾ÅÍ, ±âŸ(¿¬±¸±â°ü, Çмú¼¾ÅÍ)·Î ¼¼ºÐÈ­µË´Ï´Ù.

ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(CAT)ÀÌ °¡Àå Å« ºÎ¹®À» ¿¹Ãø

Àü ¼¼°è ³ú ¸ÅÇÎ Àåºñ ½ÃÀåÀº ÀûÀÀÁõ¿¡ µû¶ó ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(CAT), ¾çÀüÀÚ¹æ»ç ´ÜÃþÃÔ¿µ(PET), ³úÆÄ(EEG), ±â´ÉÀû ±ÙÀû¿Ü¼± ºÐ±¤¹ý(fNIRS), ±â´ÉÀû ÀÚ±â°ø¸í¿µ»ó(fMRI), ±âŸ·Î ¼¼ºÐÈ­µË´Ï´Ù. ÀÌ Áß CAT(ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ) ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ½Å°æ ÁúȯÀÇ Áø´Ü ¹× ¸ð´ÏÅ͸µ¿¡ MRI ¹× CT ½ºÄµ°ú °°Àº ½Å°æ ¿µ»ó Áø´ÜÀÇ »ç¿ë Áõ°¡°¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áõ°¡´Â °í±Þ ³ú ¸ÅÇÎ µµ±¸ÀÇ Çʿ伺¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖÀ¸¸ç, Diagnostic Imaging Dataset Statistical¿¡ µû¸£¸é, 2023³â 5¿ù, 2022³â 2¿ùºÎÅÍ 2023³â 1¿ù±îÁö ¿µ±¹¿¡¼­ º¸°íµÈ ÃÑ ¿µ»ó °Ë»ç °Ç¼ö´Â 4,340¸¸ °ÇÀ¸·Î Áý°èµÆ½À´Ï´Ù. 2023³â 1¿ù¿¡ °¡Àå ¸¹ÀÌ ½ÃÇàµÈ °Ë»ç´Â ÀÏ¹Ý ¿¢½º·¹ÀÌ(X-ray) 170¸¸ °Ç, Áø´Ü¿ë ÃÊÀ½ÆÄ(ÃÊÀ½ÆÄ) 80¸¸ °Ç, ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(CT) 50¸¸ °Ç, ÀÚ±â°ø¸í¿µ»ó(MRI) 30¸¸ °Ç ¼øÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

º´¿ø°ú Áø·á¼Ò°¡ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ´Â ÇÏÀ§ ºÎ¹®

³ú½Å°æ¿Ü°ú¿¡¼­ Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ÀÓ»óÀû ÇÊ¿ä¿Í ¼ö¿ä¸¦ ³ôÀÌ°í Á¾¾ç Á¦°Å ½Ã ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇØ ³ú ¸ÅÇÎ Àåºñ°¡ µµÀԵǰí ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ¿Ü°ú Àǻ簡 ³úÀÇ Áß¿äÇÑ À§Ä¡¸¦ Á¤È®ÇÏ°Ô Å½»öÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 8¿ù, µ¨¸® º´¿øÀº ±¹³» ÃÖÃʶó°í ÁÖÀåÇÏ´Â µ¶Æ¯ÇÑ '³ú ¸ÅÇÎ Àåºñ'¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ Àåºñ´Â ³úÁ¾¾ç Ä¡·á¸¦ °³¼±ÇÏ°í Áß¿äÇÑ ³ú ºÎÀ§ÀÇ ¼Õ»óÀ» ÇÇÇϱâ À§ÇØ ¿¬±¸¿Í ÷´Ü ±â¼úÀ» °áÇÕÇÑ °ÍÀÔ´Ï´Ù.

Áö¿ªº° Àü¸Á

¼¼°è ºê·¹ÀÎ ¸ÅÇÎ ±â±â ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹, ij³ª´Ù), À¯·´(¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, µ¶ÀÏ, ÇÁ¶û½º, ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(Àεµ, Áß±¹, ÀϺ», Çѱ¹, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç), ±âŸ Áö¿ª(Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, ¶óƾ¾Æ¸Þ¸®Ä«) µî Áö¿ªº°·Î ´õ¿í ¼¼ºÐÈ­µÇ¾î ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇコÄɾî Çõ½ÅÀ» À§ÇÑ Á¤ºÎÀÇ ¿òÁ÷ÀÓ

Á¤ºÎ´Â ÀÇ·á ÀÎÇÁ¶ó¿¡ ÁßÁ¡À» µÎ°í ÀÚ±ÝÀ» ´Ã·Á ÀÌ ºÐ¾ßÀÇ Çõ½ÅÀ» ÃËÁøÇÏ°í ÀÖÀ¸¸ç, ³ú ¸ÅÇÎ Àåºñ Á¦Á¶¾÷ü°¡ Á¦Ç°ÀÇ Á¤È®¼º, È¿À²¼º ¹× °¡°ÝÀ» °³¼±ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÏ´Â µî ÀÌ ºÐ¾ßÀÇ Çõ½ÅÀ» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ¶óµð¿ì½º(Healthcare Radius)¿¡ µû¸£¸é 2024³â 2¿ù ÃÑ ÀÇ·áºñ´Â 2023-24³â 96¾ï ´Þ·¯¿¡¼­ 2024-25³â 109¾ï ´Þ·¯·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ¶ÇÇÑ Pradhan Mantri Ayushman Bharat Health Infrastructure Mission(PMABHIM)¿¡ ´ëÇÑ ÇÒ´ç·®ÀÌ Å©°Ô Áõ°¡ÇÏ¿© 2023-24³â 254¾ï ´Þ·¯¿¡¼­ 2024-25³â 497¾ï ´Þ·¯·Î Áõ°¡Çß½À´Ï´Ù.

ºÏ¹Ì°¡ ÁÖ¿ä ½ÃÀå Á¡À¯À²À» Â÷Áö

Ä¡¸Å ¹ßº´·üÀÇ Áõ°¡´Â Ä¡¸ÅÀÇ Á¶±â ¹ß°ß°ú Áúº´ ÁøÇàÀ» ¸ð´ÏÅ͸µÇϱâ À§ÇØ ´õ ³ôÀº ¹Î°¨µµ, ÇØ»óµµ ¹× ƯÀ̼ºÀ» °¡Áø ³ú ¸ÅÇÎ Àåºñ¿¡ ÃÊÁ¡À» ¸ÂÃá ÷´Ü ½Å°æ ¿µ»ó ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, 2023³â 3¿ù, Ä¡¸Å´Â Àü ¼¼°èÀûÀ¸·Î ¸¹Àº »ç¶÷µé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ÇöÀç 5,500¸¸ ¸í ÀÌ»óÀÌ Ä¡¸Å¸¦ ¾Î°í ÀÖ½À´Ï´Ù. ±× Áß ´ëºÎºÐ(60.0% ÀÌ»ó)Àº ÁßÀú¼Òµæ ±¹°¡¿¡ °ÅÁÖÇÏ°í ÀÖ½À´Ï´Ù. ¸Å³â 1,000¸¸ ¸í¿¡ °¡±î¿î »õ·Î¿î »ç·Ê°¡ º¸°íµÇ°í ÀÖ½À´Ï´Ù. Ä¡¸ÅÀÇ °¡Àå ÈçÇÑ ÇüÅÂÀÎ ¾ËÃ÷ÇÏÀ̸Ӻ´Àº Ä¡¸Å ȯÀÚÀÇ 60-70.0%¸¦ Â÷ÁöÇÕ´Ï´Ù. Ä¡¸Å´Â Àü ¼¼°èÀûÀ¸·Î ÁÖ¿ä »ç¸Á¿øÀÎÀ̸ç, ³ëÀÎÀÇ Àå¾Ö¿Í ÀÇÁ¸¼ºÀ» À¯¹ßÇÏ´Â ÁÖ¿ä ¿øÀÎÀ¸·Î 2019³â Ä¡¸Å·Î ÀÎÇÑ °æÁ¦Àû ºñ¿ëÀº 1Á¶ 3,000¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ±× Áß ¾à 50.0%´Â ºñ°ø½Ä °£º´ÀÎÀÌ ÇÏ·ç Æò±Õ 5½Ã°£ÀÇ °£º´°ú °¨µ¶À» ÇÏ´Â µ¥ ±âÀÎÇÕ´Ï´Ù. ¿©¼ºÀº Ä¡¸Å ȯÀÚ °£º´ ½Ã°£ÀÇ 70.0%¸¦ ´ã´çÇÏ°í ÀÖÀ¸¸ç, Àå¾Ö Á¶Á¤ »ýÁ¸À²°ú »ç¸Á·üÀÌ ³ô´Ù´Â Á¡¿¡¼­ Ä¡¸ÅÀÇ ¿µÇâÀ» ºÒ±ÕÇüÀûÀ¸·Î ¹Þ°í ÀÖ½À´Ï´Ù.

¼¼°è ºê·¹ÀÎ ¸ÅÇÎ ±â±â ½ÃÀå¿¡ ÁøÃâÇÑ ÁÖ¿ä ±â¾÷À¸·Î´Â Á¦³Ê·² ÀÏ·ºÆ®¸¯, Çʸ³½º, ¸ÞµåÆ®·Î´Ð, ij³í ¸ÞµðÄà ½Ã½ºÅÛÁî, Áö¸à½º ÇïƼ´Ï¾î½º µîÀÌ ÀÖ½À´Ï´Ù. ½ÃÀå °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ Á¦ÈÞ, ÇÕº´, Àμö µîÀÇ Àü·«À» Àû¿ëÇØ »ç¾÷ È®Àå ¹× Á¦Ç° °³¹ß¿¡ ÁýÁßÇÏ´Â ±â¾÷ÀÌ ´Ã°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 5¿ù ·¹³ì½º Èú º´¿ø(Lennox Hill Hospital)Àº ³ú ¸ÅÇÎ ½Å°æ ±â¼úÀÎ ÄüÅè(Quicktome)À» µµÀÔÇÏ¿© ³ú½Å°æ ¼ö¼úÀÇ È¿À²¼ºÀ» Çâ»ó½ÃÄ×À¸¸ç, FDA ½ÂÀÎÀ» ¹ÞÀº ÀÌ Ç÷§ÆûÀº ¼ö¼ú Àü MRI ½ºÄµÀ» ÅëÇØ È¯ÀÚº° ³ú ³×Æ®¿öÅ©¸¦ ÀÚµ¿À¸·Î ¸ÅÇÎÇÕ´Ï´Ù. ÀÚµ¿À¸·Î ¸ÅÇÎÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå º¸°í¼­ °³¿ä

  • ¾÷°è ÇöȲ ºÐ¼®°ú ¼ºÀå °¡´É¼º Àü¸Á
  • Á¶»ç ¹æ¹ý°ú Åø
  • ½ÃÀå ³»¿ª
    • ºÎ¹®º°
    • Áö¿ªº°

Á¦2Àå ½ÃÀå °³¿ä¿Í ÀλçÀÌÆ®

  • Á¶»ç ¹üÀ§
  • ¾Ö³Î¸®½ºÆ®ÀÇ ÀλçÀÌÆ®¿Í ÇöÀç ½ÃÀå µ¿Çâ
    • ÁÖ¿ä ¾÷°è µ¿Çâ
    • Ãßõ»çÇ×
    • °á·Ð

Á¦3Àå °æÀï »óȲ

  • ÁÖ¿ä ±â¾÷ ºÐ¼®
  • General Electric Co.
    • °³¿ä
    • À繫 ºÐ¼®
    • SWOT ºÐ¼®
    • ÃÖ±ÙÀÇ µ¿Çâ
  • Koninklijke Philips N.V.
    • ±â¾÷ °³¿ä
    • À繫 ºÐ¼®
    • SWOT ºÐ¼®
    • ÃÖ±ÙÀÇ µ¿Çâ
  • Medtronic PLC
    • °³¿ä
    • À繫 ºÐ¼®
    • SWOT ºÐ¼®
    • ÃÖ±ÙÀÇ µ¿Çâ
  • ÁÖ¿ä Àü·« ºÐ¼®

Á¦4Àå ½ÃÀå ¼¼ºÐÈ­

  • ºê·¹ÀÎ ¸ÅÇÎ ±â±â ¼¼°è ½ÃÀå : Á¦Ç°º°
    • ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(CAT)
    • ¾çÀüÀÚ¹æ»ç ´ÜÃþÃÔ¿µ
    • ³úÆÄ°è(EEG)
    • ±â´ÉÀû ±ÙÀû¿Ü¼± ºÐ±¤¹ý(fNIRS)
    • ±â´ÉÀû ÀÚ±â°ø¸í¿µ»ó¹ý(fMRI)
    • ±âŸ(³úÀÚµµ(MEG) ½Ã½ºÅÛ, °æµÎ°³ ÀÚ±â ÀÚ±Ø(TMS) ±â±â)
  • ºê·¹ÀÎ ¸ÅÇÎ ±â±â ¼¼°è ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°
    • º´¿ø ¹× Áø·á¼Ò
    • Áø´Ü ¼¾ÅÍ
    • ±âŸ(¿¬±¸±â°ü, Çмú ¼¾ÅÍ)

Á¦5Àå Áö¿ªº° ºÐ¼®

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¼¼°è ±âŸ Áö¿ª
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦6Àå ±â¾÷ °³¿ä

  • Advanced Brain Monitoring Inc.
  • Artinis Medical Systems B.V.
  • Blackrock Microsystems, Inc.
  • Brainlab AG
  • Canon Medical Systems Corp.
  • Compumedics Ltd.
  • Gowerlabs Ltd.
  • Magstim, Inc.
  • Mindware Technologies Ltd.
  • Natus Medical Inc.
  • NIHON KOHDEN CORP.
  • Nihon Kohden Corporation
  • NIRx Medical Technologies, LLC
  • Rogue Research Inc.
  • Siemens Healthineers Co.
  • Soterix Medical, Inc.
  • Yokogawa Electric Corp.
ksm 24.06.28

Global Brain Mapping Instruments Market Size, Share & Trends Analysis Report by Product (Computed Axial Tomography (CAT), Position Emission Tomography, Electroencephalography (EEG), Functional Near-Infrared Spectroscopy (fNIRS), Functional Magnetic Resonance Imaging (fMRI), and Others) and by End Users (Hospitals and Clinics, Diagnostic Centers, and Others) Forecast Period (2024-2031)

The global brain mapping instruments Market is anticipated to grow at a considerable CAGR of 6.1% during the forecast period (2024-2031). The global brain mapping instruments market is fueled by advancements in neuroscience research, the increasing prevalence of neurological disorders, technological innovations, government, and private funding, clinical applications, increasing awareness and education, globalization, partnerships, and regulatory landscape. Advancements in neuroscience research, the need for sophisticated tools to capture detailed data, and the increasing prevalence of neurological disorders like Alzheimer's, Parkinson's, epilepsy, and stroke drive the demand for brain mapping instruments. Government and private funding initiatives, as well as increased awareness about brain health and early detection, contribute to market growth. Collaborations between industry players, academic institutions, and research organizations foster innovation in brain mapping instruments.

Market Dynamics

Increased Diagnosis and Monitoring Needs

Global health is at risk from neurological disorders, which call for precise diagnosis and ongoing observation. Tools for brain mapping are essential for the advancement of disease and the effectiveness of treatment. According to the World Health Organization (WHO), in March 2024, there was a significant global prevalence of neurological conditions, affecting over 3.0 billion individuals. Neurological conditions have emerged as the primary cause of ill health and disability globally. The overall burden of disability, illness, and premature death caused by these conditions has witnessed an 18.0% increase. Notably, access to treatment for neurological conditions varies, with high-income countries having substantially more neurological professionals per 100,000 individuals compared to low- and middle-income countries, where over 80.0% of neurological deaths and health loss occur.

Increased Funding for Brain Mapping Research

Brain Connects offers significant funding for brain mapping research, promoting the development of novel technologies and propelling market expansion via partnerships, technology transfer, and research product commercialization. For instance, National Institute of Neurological Disorders and Stroke (.gov), in September 2023, the NIH BRAIN Initiative launched projects to develop innovative technologies to map the brain in detail. The initiative aims to uncover the logic of the brain's neural code, helping to understand how it makes us who we are and how it could be re-wired to treat brain diseases. The initial round of BRAIN CONNECTS awards supports 11 grants, totaling $150.0 million over five years. The projects will use cutting-edge technology to image and analyze brain connectivity, develop pipelines for data collection and analysis, and develop complementary brain mapping technologies.

Market Segmentation

Our in-depth analysis of the global brain mapping instruments market includes the following segments by product and end-user:

  • Based on the product, the market is sub-segmented into computed axial tomography (CAT), positron emission tomography, electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), functional magnetic resonance imaging (fMRI), and other (magnetoencephalography (MEG) systems, and transcranial magnetic stimulation (TMS) devices).
  • Based on end-users, the market is sub-segmented into hospitals and clinics, diagnostic centers, and others (research institutes and academic centers).

Computed Axial Tomography (CAT) is Projected to Emerge as the Largest Segment

Based on the disease indication, the global brain mapping instruments market is sub-segmented into computed axial tomography (CAT), positron emission tomography, electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), functional magnetic resonance imaging (fMRI), and others. Among these, the computed axial tomography (CAT) sub-segment is expected to hold the largest share of the market. The primary factor supporting the segment's growth includes the use of neuroimaging, such as MRIs and CT scans, which is growing in the diagnosis and monitoring of neurological diseases. This rise has been prompted by the need for sophisticated brain mapping tools. According to the Diagnostic Imaging Dataset Statistical, in May 2023, the total number of imaging tests reported in England from February 2022 to January 2023 was 43.4 million. In January 2023, the most commonly performed tests were Plain Radiography (X-ray) with 1.7 million, followed by Diagnostic Ultrasonography (Ultrasound) with 0.8 million, Computerized Axial Tomography (CT Scan) with 0.5 million, and Magnetic Resonance Imaging (MRI) with 0.3 million.

Hospitals and Clinics Sub-segment to Hold a Considerable Market Share

To enhance the clinical need and demand for precision medicine in neurosurgery and improve patient outcomes during tumor removal, a brain mapping gadget is being introduced. This technology allows surgeons to navigate essential brain locations with accuracy. For instance, in August 2022, Delhi Hospital launched a unique "brain mapping device," claiming it is the first of its kind in the country. The device combines research and advanced technology to improve treatment for brain tumors and avoid damage to critical brain areas.

Regional Outlook

The global brain mapping instruments market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Government for Healthcare Innovation in the Asia-Pacific Region

The government's focus on healthcare infrastructure and increased funding fosters innovation in the sector, including support for brain mapping instrument manufacturers to improve product accuracy, efficiency, and affordability. According to Healthcareradius, in February 2024, the total healthcare expenditure showed an increase from $9.6 billion in 2023-24 to $10.9 billion in 2024-25. Additionally, there has been a significant increase in the allocation for the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PMABHIM), which has risen from $25.4 billion in 2023-24 to $49.7 billion in 2024-25.

North America Holds Major Market Share

The increasing dementia prevalence prompts investments in advanced neuroimaging technologies, focusing on brain mapping instruments with higher sensitivity, resolution, and specificity for early dementia detection and disease progression monitoring. According to the World Health Organization, in March 2023, Dementia affects a significant number of individuals globally, with over 55.0 million individuals currently living with the condition. The majority of these individuals (over 60.0%) reside in low- and middle-income countries. Each year, there are nearly 10.0 million new cases reported. Alzheimer's disease, the most common form of dementia, accounts for 60-70.0% of these cases. Dementia is a leading cause of death and contributes to disability and dependency among older individuals globally. In 2019, the economic cost of dementia was estimated at $1.3 trillion, with approximately 50.0% of these expenses attributed to informal carers, which provide an average of 5 hours of care and supervision per day. Women are disproportionately affected by dementia, both in terms of higher disability-adjusted life years and mortality rates, in addition to being responsible for 70.0% of the caregiving hours for individuals with dementia.

The major companies serving the global brain mapping instruments market include General Electric Co., Koninklijke Philips N.V., Medtronic PLC, Canon Medical Systems Corp., and Siemens Healthineers Co., among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For instance, in May 2023, Lenox Hill Hospital adopted Quicktome, a brain-mapping neurotechnology, to improve neurosurgery efficiency. The FDA-cleared platform uses MRI scans to automatically map a patient's unique brain network before surgery.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Industry Trends
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. General Electric Co.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Koninklijke Philips N.V.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Medtronic PLC
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Brain Mapping Instruments Market by Product
    • 4.1.1. Computed Axial Tomography (CAT)
    • 4.1.2. Position Emission Tomography
    • 4.1.3. Electroencephalography (EEG)
    • 4.1.4. Functional Near-Infrared Spectroscopy (fNIRS)
    • 4.1.5. Functional Magnetic Resonance Imaging (fMRI)
    • 4.1.6. Other (Magnetoencephalography (MEG) Systems, and Transcranial Magnetic Stimulation (TMS) Devices)
  • 4.2. Global Brain Mapping Instruments Market by End-user
    • 4.2.1. Hospitals and Clinics
    • 4.2.2. Diagnostic Centers
    • 4.2.3. Others (Research Institutes and Academic Centers)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East & Africa

6. Company Profiles

  • 6.1. Advanced Brain Monitoring Inc.
  • 6.2. Artinis Medical Systems B.V.
  • 6.3. Blackrock Microsystems, Inc.
  • 6.4. Brainlab AG
  • 6.5. Canon Medical Systems Corp.
  • 6.6. Compumedics Ltd.
  • 6.7. Gowerlabs Ltd.
  • 6.8. Magstim, Inc.
  • 6.9. Mindware Technologies Ltd.
  • 6.10. Natus Medical Inc.
  • 6.11. NIHON KOHDEN CORP.
  • 6.12. Nihon Kohden Corporation
  • 6.13. NIRx Medical Technologies, LLC
  • 6.14. Rogue Research Inc.
  • 6.15. Siemens Healthineers Co.
  • 6.16. Soterix Medical, Inc.
  • 6.17. Yokogawa Electric Corp.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦